Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE vs ZEGALOGUE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus aged 6 years and older
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Terminal elimination half-life is 5-7 hours in healthy adults; in hepatic impairment, half-life may be prolonged up to 12 hours, requiring dose adjustment.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Dasiglucagon is metabolized via proteolytic degradation into smaller peptides and amino acids; CYP enzymes are not involved.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Primarily renal excretion of unchanged drug (approximately 70-80%) and minor hepatic metabolism with biliary/fecal elimination (10-15%).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Approximately 85% bound to albumin and alpha-1-acid glycoprotein.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
0.6-0.8 L/kg, indicating moderate tissue distribution with concentrations in tissues approximately 1.5 times plasma.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Oral: 40-50% (due to first-pass metabolism); Intramuscular: 90-100%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2). Not recommended for use in patients with end-stage renal disease (e GFR <15 m L/min/1.73 m2) due to lack of data.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A). Not studied in moderate or severe hepatic impairment (Child-Pugh class B or C); use not recommended in these patients.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Not indicated for pediatric patients; safety and efficacy in patients <18 years have not been established.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No specific dose adjustment required based on age alone. However, dosing should be cautious due to potential for decreased renal function or comorbidities; monitor renal function and volume status.
None.
None.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Risk of serious hypersensitivity reactions including anaphylaxis,May cause nausea and vomiting,Risk of hypoglycemia if used in patients with insulinoma or glucagonoma,May increase blood pressure and heart rate
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Pheochromocytoma,Insulinoma,Known hypersensitivity to dasiglucagon or any excipients
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No specific food interactions. After recovery, administer oral carbohydrates to replenish liver glycogen and prevent recurrent hypoglycemia. Avoid alcohol as it may impair glucose recovery.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk cannot be excluded; use only if benefit outweighs risk. Fetal risks: potential for maternal hypoglycemia-induced fetal distress if not treated.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No data on presence in human milk; dasiglucagon is a peptide likely degraded in GI tract. M/P ratio not determined. Caution in breastfeeding; consider risk of infant exposure vs benefit of treating maternal hypoglycemia.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
No pharmacokinetic data in pregnancy; dosing adjustments not recommended. Use standard dose (0.6 mg) for severe hypoglycemia regardless of trimester.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
ZEGALOGUE (dasiglucagon) is a soluble glucagon analog indicated for severe hypoglycemia. It is stable in liquid form, avoiding reconstitution. Onset of action is 10-15 minutes, with blood glucose rise similar to native glucagon. Note that it can cause nausea and vomiting; if patient is unconscious, place in recovery position. Do not use if patient has pheochromocytoma, insulinoma, or known hypersensitivity. Store at room temperature.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
Use only for severe hypoglycemia when patient is unable to take carbs orally or is unconscious.,Inject into buttock, thigh, or abdomen; no need to mix or reconstitute.,After injection, call emergency services immediately.,Administer supplemental carbs (if conscious and can swallow) after blood glucose responds.,Common side effects: nausea, vomiting, headache, injection site pain.,Store at controlled room temperature (20-25°C); do not freeze.
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE vs ZEGALOGUE, answered by our medical review team.
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. ZEGALOGUE is a GnRH Antagonist that works by ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE and ZEGALOGUE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. The standard adult dose of ZEGALOGUE is: Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE and ZEGALOGUE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. ZEGALOGUE is classified as Category C. Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.